Alexandra Kropotova Net Worth

Alexandra Kropotova biography

Dr. Alexandra Kropotova serves as Independent Director of the Company. Dr. Kropotova was appointed as a member of our Board in October 2020 and currently serves as a member of the newly formed Science and Technology Committee of the Board. Dr. Kropotova is a biopharmaceutical executive with expertise in all phases of global clinical development, translational medicine and medical affairs. Since 2016, she has served as Vice President, Global Specialty R&D, Respiratory & Inflammation Therapeutic Area at Teva Pharmaceuticals (TASE:TEVA), where she leads the design and execution of global clinical development programs, the majority of which are biologic candidates for pulmonary, chronic inflammatory or autoimmune indications. Prior to joining Teva, between 2007-2016, Dr. Kropotova served in various roles at Sanofi (EPA:SAN), including Vice President, Strategy & Strategic Planning Head, North American Medical Affairs; Associate Vice President and subsequently Vice President, Immuno-Inflammation, Global R&D; and Senior Medical Director, Respiratory, Allergy & Anti-Infectives. Prior to joining Sanofi, she served in various roles at Pfizer Inc. (NYSE:PFE) from 2002-2007, most recently as Director & Head of Global Clinical Respiratory and Analgesics. Dr. Kropotova received her Master of Business Administration Degree from Ohio University Graduate School of Business, Athens, Ohio, and her Medical Degree in Internal Medicine from the Vladivostok State Medical University, Vladivostok, Russia. The Company believes Dr. Kropotova’s experience and knowledge as a medical professional and biologics development experience across multiple therapeutic areas along with her experience in various leadership roles in successful pharmaceutical companies, will be a valuable addition to the Board and the Company.

How old is Alexandra Kropotova?

Alexandra Kropotova is 48, he's been the Independent Director of iBio Inc since 2020. There are 15 older and no younger executives at iBio Inc. The oldest executive at iBio Inc is Seymour Flug, 84, who is the Independent Director.

What's Alexandra Kropotova's mailing address?

Alexandra's mailing address filed with the SEC is C/O IBIO, INC., 8800 HSC PARKWAY, BRYAN, TX, 77807.

Insiders trading at iBio Inc

Over the last 14 years, insiders at iBio Inc have traded over $99,626,328 worth of iBio Inc stock and bought 15,716,013 units worth $10,660,994 . The most active insiders traders include Capital Ltd Portfolio Servi..., Carl Desantis и William D Clark. On average, iBio Inc executives and independent directors trade stock every 98 days with the average trade being worth of $1,893,515. The most recent stock trade was executed by Martin Brenner on 1 November 2023, trading 4,881 units of IBIO stock currently worth $1,318.

What does iBio Inc do?

ibio is a contract development and manufacturing organization equipped to take clients from the early stages of product selection through regulatory approval and commercial product launch. ibio’s technology platform and facility capabilities are applicable to the development of biotherapeutics, vaccines, diagnostic products, and certain types of medical devices – and often provide significant time and value advantages over traditional approaches. ibio’s lab to launch capabilities assure the most rapid manufacturing support to reach the clinic. ibio’s team is comprised of knowledgeable protein scientists, microbiologists and manufacturing and regulatory experts, all of whom add significant expertise and value throughout the entire process. the same team and facility that produces preclinical and clinical material will be the same team producing your product for market launch; contributing to the seamless scale-up process the ibio technology platform creates.

iBio Inc executives and stock owners

iBio Inc executives and other stock owners filed with the SEC include:

• Thomas Isett,
  Chairman of the Board, Chief Executive Officer
• Thomas F. Isett III,
  CEO, Pres & Chairman
• Robert Kay,
  Interim Secretary, Interim Treasurer, Director
• Randy Joe Maddux,
  Chief Operating Officer
• Dr. Martin B. Brenner D.V.M., Ph.D.,
  Chief Scientific Officer
• Robert Erwin,
  President
• Robert B. Kay,
  Interim Sec. & Interim Treasurer
• James Hill,
  Independent Director
• John McKey,
  Independent Director
• Seymour Flug,
  Independent Director
• Glenn Chang,
  Independent Director
• Stephen Kilmer,
  Investor Relations
• Gary Sender,
  Independent Director
• Alexandra Kropotova,
  Independent Director
• Linda Armstrong,
  Independent Director
• John Delta,
  Principal Financial Officer, Principal Accounting Officer
• Carlos Picosse,
  Chief Exec. Officer of IBio Brazil
• Dr. Melissa Berquist Ph.D.,
  VP and Head of Vaccines & Animal Health
• Lisa Middlebrook,
  Chief HR Officer
• Robert Matthew Lutz,
  Chief Financial & Bus. Officer
• Mark A Giannone,
  Chief Financial Officer
• Kenneth Bryan Dart,
  10% owner
• Carl Desantis,
  10% owner
• Philip K. Russell,
  Director
• Arthur Y Elliott,
  Director
• Capital Ltd Portfolio Servi...,
  
• Ryan E Terence,
  Chief Scientific Officer
• Randy Joe Maddux,
  Chief Operating Officer
• Robert Matthew Lutz,
  See Remarks
• James P. Mullaney,
  Chief Financial Officer
• Evert B. Schimmelpennink,
  Director
• E Gerald Kay,
  10% owner
• Jules A. Musing,
  Director
• William D Clark,
  Director
• Martin Brenner,
  See Remarks
• Felipe Duran,
  Chief Financial Officer